Lakewood-Amedex is a privately held pharmaceutical company dedicated to addressing significant unmet medical needs in the treatment of serious infectious diseases. They are focused on developing a broad portfolio of antimicrobial and antifungal therapeutics called bisphosphocins, which have demonstrated rapid bactericidal action against over 70 different bacterial strains, including antibiotic-resistant and biofilm forming bacteria. With the growing crisis of multidrug-resistant infections, Lakewood-Amedex is dedicated to addressing the most life-threatening disease indications.

Their lead therapeutic candidate, Nu-3, is a novel synthetic broad-spectrum antimicrobial that has shown effectiveness in killing a wide range of Gram-positive, Gram-negative, and antibiotic-resistant bacteria. Nu-3 recently completed a Phase 1/2a clinical trial, demonstrating no treatment-related adverse events and showing a trend toward efficacy. Lakewood-Amedex's mission is to improve patient outcomes and significantly reduce the urgent threats posed by increasingly antibiotic-resistant bacterial strains.

They are committed to resolving urgent medical needs and are actively conducting a Phase 2a clinical trial to provide robust clinical data by 2023. For more information, you can contact Lakewood-Amedex at their University Park, FL location or visit their website for the latest news and updates